Campaign group MRSA Action cautiously welcomed the new findings and urged the government to provide more funding for research into fighting infections.

A study of the new drug, which is applied as a gel into patients' noses, showed methicillin-resistant Staphylococcus aureus bacteria (MRSA) did not develop resistance to the compound despite being exposed to it 55 times.